Chemed (NYSE:CHE) Price Target Raised to $625.00

Key Points

• Oppenheimer raised Chemed’s price target to $625 from $590 and maintained an “outperform” rating, implying 16.88% potential upside from the reported share price.
• Chemed exceeded third-quarter expectations, reporting EPS of $6.75 versus $6.44 expected and revenue of $690.9 million versus $685.0 million; management indicated full-year adjusted EPS could reach or slightly exceed the high end of its prior guidance.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and $590.60 target. VITAS delivered strong growth, but Roto-Rooter’s profitability declined, while recent insider activity was marked by net selling.

Chemed (NYSE:CHE - Get Free Report) had its price objective raised by investment analysts at Oppenheimer from $590.00 to $625.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has an "outperform" rating on the stock. Oppenheimer's price target would indicate a potential upside of 16.88% from the stock's current price.

Several other equities research analysts also recently issued reports on CHE. Weiss Ratings upgraded shares of Chemed from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, October 8th. Wall Street Zen raised Chemed from a "buy" rating to a "strong-buy" rating in a research report on Saturday, October 10th. Royal Bank Of Canada upped their price objective on Chemed from $436.00 to $548.00 and gave the company a "sector perform" rating in a research note on Thursday, July 30th. Jefferies Financial Group raised Chemed from a "hold" rating to a "buy" rating and raised their price objective for the company from $520.00 to $620.00 in a research report on Wednesday. Finally, Bank of America reiterated a "neutral" rating on shares of Chemed in a research note on Wednesday, July 29th. Three analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $590.60.

Chemed Stock Performance

Shares of NYSE CHE opened at $534.72 on Thursday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.89 and a current ratio of 0.91. The stock has a 50 day moving average price of $514.55 and a 200 day moving average price of $462.04. The stock has a market capitalization of $6.99 billion, a PE ratio of 26.86, a price-to-earnings-growth ratio of 2.06 and a beta of 0.51. Chemed has a 52 week low of $365.20 and a 52 week high of $562.24.

Chemed (NYSE:CHE - Get Free Report) last released its quarterly earnings data on Tuesday, October 27th. The company reported $6.75 EPS for the quarter, beating the consensus estimate of $6.44 by $0.31. The company had revenue of $690.94 million during the quarter, compared to the consensus estimate of $685.04 million. Chemed had a return on equity of 31.77% and a net margin of 10.60%. The firm's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.27 EPS. Analysts predict that Chemed will post 23.55 earnings per share for the current fiscal year.

Insider Transactions at Chemed

In other Chemed news, Director Patrick P. Grace sold 190 shares of the company's stock in a transaction on Friday, July 31st. The stock was sold at an average price of $532.00, for a total value of $101,080.00. Following the transaction, the director directly owned 3,533 shares of the company's stock, valued at $1,879,556. This represents a 5.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction on Monday, September 28th. The stock was sold at an average price of $513.45, for a total value of $1,026,900.00. Following the sale, the chief executive officer directly owned 66,418 shares of the company's stock, valued at $34,102,322.10. This represents a 2.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 9,190 shares of company stock worth $4,833,160 over the last quarter. Company insiders own 3.33% of the company's stock.

Institutional Trading of Chemed

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Chemed in the 2nd quarter valued at approximately $34,000. Versant Capital Management Inc raised its stake in shares of Chemed by 7,500.0% during the second quarter. Versant Capital Management Inc now owns 76 shares of the company's stock valued at $35,000 after acquiring an additional 75 shares during the last quarter. Keating Financial Advisory Services Inc. acquired a new position in shares of Chemed during the second quarter worth $36,000. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Chemed by 65.3% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 81 shares of the company's stock worth $38,000 after purchasing an additional 32 shares during the period. Finally, Global Retirement Partners LLC bought a new stake in shares of Chemed in the second quarter worth $49,000. Institutional investors and hedge funds own 95.85% of the company's stock.

Chemed News Roundup

Here are the key news stories impacting Chemed this week:

• Positive Sentiment: Chemed exceeded third-quarter expectations: Adjusted EPS rose 28.1% year over year to $6.75, surpassing the $6.44 consensus estimate, while revenue increased 10.6% to $690.9 million versus expectations of $685.0 million. Chemed Reports Third-Quarter 2026 Results
• Positive Sentiment: VITAS delivered strong operating momentum: Hospice revenue increased 12.2% to $457.4 million, average daily census grew 9.4% to 24,428 and admissions increased 7.2%. Adjusted EBITDA excluding Medicare Cap rose 31.4%, with the margin expanding 318 basis points to 20.2%. Chemed Corp. Bottom Line Climbs in Q3
• Positive Sentiment: Management said full-year 2026 adjusted EPS should be at or slightly above the high end of the guidance issued in July, improving the outlook following the quarterly beat. Chemed Third-Quarter Revenue Rises 10.6%
• Positive Sentiment: Jefferies upgraded CHE to Buy, citing additional upside potential, while BofA raised its price target to $555 from $550 and maintained a Buy rating. Jefferies Upgrade and Price Target
• Neutral Sentiment: Chemed repurchased approximately 125,000 shares for $66 million and spent about $62.5 million to reacquire California Roto-Rooter franchise territories, supporting long-term growth but reducing near-term cash balances. Chemed Earnings Results
• Negative Sentiment: Roto-Rooter results were comparatively soft: Revenue grew 7.5% to $233.5 million, but segment net income declined 1.8%, adjusted EBITDA fell 2.5% and the margin contracted 213 basis points to 20.6%. Chemed Segment Results
• Negative Sentiment: Recent reported insider activity showed selling by executives, including CEO Kevin McNamara, with no disclosed insider purchases; this may modestly temper sentiment despite the strong operating results. Chemed Insider Activity

About Chemed

Chemed Corporation NYSE: CHE is a Cincinnati, Ohio-based company that provides healthcare and residential and commercial services through two operating businesses: VITAS Healthcare and Roto-Rooter. Its operations serve customers primarily in the United States, with Roto-Rooter also providing services in Canada.

VITAS Healthcare is a provider of hospice and palliative care for individuals with advanced illnesses. The business delivers care in patients' homes, hospice inpatient units, hospitals, nursing facilities and other care settings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.